GFAP and early-onset autosomal dominant Alzheimer disease: Despite the associations with disease severity and cognition, it is still not clear whether both serum NfL and serum GFAP are specific for CSVD in our cohort of elderly patients or whether both biomarkers may also reflect comorbid neurodegenerative pathologies such as impending Alzheimer’ disease [48,49].